Document is current
Any future updates will be listed below
-
Authors
Yassin, Ahmed S.
Noordman, Alwin B. P.
Maass, Alexander H.
Rienstra, Michiel
Blaauw, Yuri
- License Information
-
More Information
Article History
Received: 12 November 2025
Accepted: 10 February 2026
First Online: 18 March 2026
Declarations
:
: Conflict of interest: None of the authors have any conflicts of interest to declare, other than mentioned below; MR: Consultancy fees from Bayer (OCEANIC-AF national PI), InCarda Therapeutics (RESTORE-SR national PI), Novartis to the institution. Speaker fee from Daiichi-Sankyo, Pfizer to the institution. YB: Consultancy fees from Abbott, Boston Scientific, Biosense Webster [to the institution]. A.H.M. is a consultant for Boston Scientific and Medtronic [to the institution]. Disclosure of funding: None of the authors have any source of funding to declare, other than mentioned below.MR: Unrestricted research grant from the Dutch Heart Foundation and is conducted in collaboration with and supported by the Dutch CardioVascular Alliance, 01-002-2022-0118 EmbRACE. Unrestricted research grant from ZonMW and the Dutch Heart Foundation; DECISION project 848090001. Unrestricted research grants from the Netherlands Cardiovascular Research Initiative: an initiative with support of the Dutch Heart Foundation; RACE V (CVON 2014–9), RED-CVD (CVON2017-11). Unrestricted research grant from Top Sector Life Sciences & Health to the Dutch Heart Foundation (PPP Allowance; CVON-AI (2018B017)). Unrestricted research grant from the European Union’s Horizon 2020 research and innovation programme under grant agreement; EHRA-PATHS (945260). YB: Research Grant from Boston Scientific.
